Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database

被引:3
|
作者
Liu, Leping [1 ]
Zheng, Hong [2 ]
Chen, Shanshan [3 ]
Wang, Shengfeng [4 ,5 ,6 ]
Yang, Minghua [1 ,6 ,7 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pediat, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Pharm, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, MOE Key Lab Rare Pediat Dis, Changsha, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Hunan Clin Res Ctr Pediat Canc, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
low-molecular-weight heparin; heparin-induced thrombocytopenia; characteristics; treatments; pharmacovigilance; ENOXAPARIN-INDUCED THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; SKIN NECROSIS; PATIENT; RIVAROXABAN; MANAGEMENT; THROMBOSIS; ARTERIAL; FONDAPARINUX;
D O I
10.3389/fphar.2023.1247253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.Methods: We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.Results: Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8 days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.Conclusion: LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Heparin "hitts" again - Acute thrombocytopenia caused by the erroneous re-exposition with a low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombosis (HITT)
    Goti, F
    Korte, W
    Gianom, D
    Decurtins, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 917 - 918
  • [42] Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients
    Junqueira, Daniela R. G.
    Perini, Edson
    Penholati, Raphael R. M.
    Carvalho, Maria G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (09):
  • [43] HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS WITH SPINAL ISCHEMIA - RECOVERY OF PLATELET COUNT FOLLOWING A CHANGE TO A LOW-MOLECULAR-WEIGHT HEPARIN
    MAURIN, N
    BINIEK, R
    HEINTZ, B
    KIERDORF, H
    INTENSIVE CARE MEDICINE, 1991, 17 (03) : 185 - 186
  • [44] HEPARIN-INDUCED THROMBOCYTOPENIA AND PENTOSAN POLYSULFATE - TREATMENT WITH A LOW-MOLECULAR-WEIGHT HEPARIN DESPITE INVITRO PLATELET-AGGREGATION
    VITOUX, JF
    RONCATO, M
    HOURDEBAIGT, P
    AIACH, M
    FIESSINGER, JN
    THROMBOSIS AND HAEMOSTASIS, 1986, 55 (02) : 294 - 295
  • [45] THROMBOCYTOPENIA AFTER A LOW-MOLECULAR-WEIGHT HEPARIN
    CHIN, SP
    ALVADO, G
    LEMOINE, P
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 1992, 11 (05): : 587 - 591
  • [46] LOW-MOLECULAR-WEIGHT HEPARIN IN A PATIENT WITH THROMBOCYTOPENIA INDUCED BY HEPARIN AND TREATED WITH A CARDIOPULMONARY BYPASS
    PARAMA, JA
    LLORENS, R
    DEBURUAGA, JS
    ROCHA, E
    MEDICINA CLINICA, 1994, 102 (16): : 637 - 638
  • [47] Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings
    Greinacher, A.
    Alban, S.
    Omer-Adam, M. A.
    Weitschies, W.
    Warkentin, T. E.
    THROMBOSIS RESEARCH, 2008, 122 (02) : 211 - 220
  • [48] COMPARATIVE HEPARIN-INDUCED THROMBOCYTOPENIC RESPONSE WITH LOW-MOLECULAR-WEIGHT HEPARIN AND A SYNTHETIC PENTASACCHARIDE
    PIFARRE, R
    WALENGA, JM
    KOZA, MJ
    KHENKINA, Y
    FAREED, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1319 - 1319
  • [49] LOW-MOLECULAR-WEIGHT HEPARIN-INDUCED THROMBOCYTOPENIA AND SKIN NECROSIS DISTANT FROM INJECTION SITES
    BALESTRA, B
    QUADRI, P
    BIASIUTTI, FD
    FURLAN, M
    LAMMLE, B
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1994, 53 (01) : 61 - 63
  • [50] HEPARIN-INDUCED THROMBOCYTOPENIA - INVITRO STUDIES WITH LOW-MOLECULAR-WEIGHT HEPARINOID, ORG-10172
    CHONG, BH
    ISMAIL, F
    CADE, J
    GALLUS, AS
    GORDON, S
    CHESTERMAN, CN
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 308 - 308